Classement en actions
#2339
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Capitalisation boursière
$8.97B
Changement (1 jour)
0.37%
Changement (1 an)
192.01%
Échange Immunovant, Inc. (IMVT)
Le prix IMVT avec la capitalisation boursière de B
Capitalisation boursière de Immunovant, Inc.(IMVT)
Capitalisation boursière: $8.97B
En August 2026, Immunovant, Inc. a une capitalisation boursière de $8.97B. Cela fait de Immunovant, Inc. la 2339th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Immunovant, Inc. du 2019 au 2026
IMVT par rapport au top 5 des plus populaires stocks
| Prix pour IMVT |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.118T
|
+56,928.00%
|
|
|
|
|
$4.548T
|
+50,573.77%
|
|
|
|
|
$4.168T
|
+46,345.62%
|
|
|
|
|
$3.632T
|
+40,366.55%
|
|
|
|
|
$2.806T
|
+31,166.74%
|
